Skip to content
Open access

Genotype-driven tumor ecosystems drive immune evasion and immunotherapy resistance in melanoma

Sep 2026 · Molecular Cancer · Vol 25 · 0 citations · 51 references
Medicine

TL;DR

This study links an understudied melanoma driver to specific immune-evasion mechanisms and identifies EGFR inhibition as a candidate strategy to improve outcomes in patients with NF1-mutant melanoma resistant to immunotherapy.

Abstract

Genetic and transcriptional alterations in cancer cells shape their interactions with immune and stromal compartments, thereby influencing tumor progression, immune evasion, and response to immune checkpoint inhibitors (ICIs). Yet, how these interactions are spatially organized within melanoma and how they relate to clinical outcome remains incompletely understood. We used spatial multi-omic profiling on melanoma tissues from patients, compared those with loss-of-function mutations in the Neurofibromin 1 (NF1) tumor suppressor gene to those with intact NF1, and integrated these results with functional studies and subsequent gene expression changes observed in patient-derived melanoma models and an immunotherapy-resistant syngeneic mouse model. Spatial multi-omic analysis of melanoma tissues from patients identified 12 meta-niches composed of distinct cell populations with unique molecular features. Although all tumors contained these meta-niches, those enriched in immunosuppressive cancer-associated fibroblasts (CAFs) and macrophages were significantly more common in tumors with NF1 loss. Conversely, niches enriched in cytotoxic CD8+ T cells were significantly reduced. In both human and mouse melanoma, NF1 loss was associated with impaired antigen-presentation programs and reduced CD8+ T cell infiltration. Mechanistically, EGFR signaling emerged as a prominent feature of NF1-deficient melanoma ecosystems and correlated with reduced expression of antigen-presentation genes and T cell exclusion. EGFR inhibition restored the expression of antigen-presentation programs and enhanced antitumor immune responses in a syngeneic Nf1 knockdown model resistant to ICIs. These findings define spatially organized, functionally distinct meta-niches enriched in NF1-mutant melanoma that may contribute to their aggressive disease features and poor ICI response. Our study links an understudied melanoma driver to specific immune-evasion mechanisms and identifies EGFR inhibition as a candidate strategy to improve outcomes in patients with NF1-mutant melanoma resistant to immunotherapy.

Read PDF

Similar papers

Open access Oct 2026

Integrated spatial and single-cell transcriptomics uncover IFI6⁺ regulatory T-cells and SPP1⁺ macrophages immunosuppressive niches in colorectal cancer.

This study uncovered previously unrecognized immunosuppressive cell populations and key immune regulators that advance understanding of CRC immune evasion and highlight potential targets for personalized immunotherapy.

Dominika Miroszewska, Shi-Yang Song, Víctor Urbiola-Salvador et al. · 0 citations
Open access Sep 2026

p38α orchestrates BRAFV600E-melanoma progression and immunotherapy response via tumor fitness and immune microenvironment modulation

It is reported that, in an UVB induced Braf V600E-mutated spontaneous mouse melanoma model, p38α contributes to tumor fitness and anti-tumor immune responses, showing that p38α inhibition sensitizes tumors to anti-PD1.

Paula Granado-Martínez, K. McGrail, Roberto Orsenigo et al. · 0 citations
Oct 2026

Epigenetic Priming Sensitizes Metastatic Breast Cancer to Checkpoint Blockade by Rewiring the Tumor-Immune Microenvironment.

Work using metastatic mouse models shows that the antitumor response is multifactorial, comprising downregulation of myeloid-mediated CD8+ T-cell suppression along with increased B-cell and plasma cell activation, antibody production, and tertiary lymphoid structure (TLS) maturation.

Y. Senent, R. Manguso · 0 citations
Review Open access Sep 2026

Tumor-immune spatiotemporal co-evolution: A new paradigm for understanding and overcoming therapy resistance in metastatic castration-resistant prostate cancer (Review)

S spatiotemporal co-evolution is established as a unifying framework that transforms mCRPC from a uniformly fatal disease into a chronically manageable condition through precisely timed, spatially informed and mechanistically rational interventions.

Li Yan, Xiao-Ke Sun, Peng-Xiao Su · 0 citations
Open access Sep 2026

The Impact of SF3B1 Mutations on the Tumor Microenvironment and Response to Immunotherapy

Cancer genomes shape the immune landscape within the tumor microenvironment (TME), thereby influencing host antitumor immunity. Identifying somatic mutations that modulate the TME is critical for selecting patients most likely to benefit from immunotherapy. Here, by integrating a transcriptome‐based predictive model wi...

K. Cho, Byungho Lim · 0 citations
Review Open access Sep 2026

TREM2⁺ tumor-associated macrophages in cancer: context-dependent biology, biomarkers and precision immunotherapy.

A context-dependent framework integrating macrophage heterogeneity, immunometabolism, spatial biology, biomarker development, and therapeutic decision-making to advance precision immunotherapy is proposed.

Xue-Jun Guo, Jing-Ya Yu, Xiao-Yan Lin et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.